Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control

<i>Background and Objectives:</i> Patients with type 2 diabetes are at a higher risk of postoperative complications, such as infections, delayed wound healing, and increased mortality compared to non-diabetic patients. <i>Materials and Methods:</i> This prospective randomized...

Full description

Saved in:
Bibliographic Details
Main Authors: Sang Hun Kim, Sang Min Yoon, Ji Hye Ahn, Yoon Ji Choi
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/3/523
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850205503783698432
author Sang Hun Kim
Sang Min Yoon
Ji Hye Ahn
Yoon Ji Choi
author_facet Sang Hun Kim
Sang Min Yoon
Ji Hye Ahn
Yoon Ji Choi
author_sort Sang Hun Kim
collection DOAJ
description <i>Background and Objectives:</i> Patients with type 2 diabetes are at a higher risk of postoperative complications, such as infections, delayed wound healing, and increased mortality compared to non-diabetic patients. <i>Materials and Methods:</i> This prospective randomized study aims to compare the effects of two anesthetics, remimazolam and propofol, on blood glucose levels and immune function in diabetic patients undergoing surgery. Seventy-four diabetic patients undergoing general anesthesia were randomly assigned to receive either remimazolam or propofol. Plasma blood glucose levels, anti-inflammatory markers, and insulin levels were measured during the perioperative period. <i>Results:</i> No statistically significant differences were observed between the remimazolam and propofol groups in terms of neutrophil-to-lymphocyte ratio, anti-inflammatory markers, or glucose levels during the perioperative period (<i>p</i> value > 0.05). <i>Conclusions:</i> These results suggest that there is no difference between propofol and remimazolam in immune function deterioration that occurs due to surgical stress. This study is limited by its small sample size, and in future, larger trials could be conducted to find differences in the effects of blood sugar levels and serum inflammatory markers between the two groups.
format Article
id doaj-art-e2feac06e649446fa84f57d2d4110612
institution OA Journals
issn 1010-660X
1648-9144
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-e2feac06e649446fa84f57d2d41106122025-08-20T02:11:04ZengMDPI AGMedicina1010-660X1648-91442025-03-0161352310.3390/medicina61030523Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized ControlSang Hun Kim0Sang Min Yoon1Ji Hye Ahn2Yoon Ji Choi3Department of Anesthesiology and Pain Medicine, College of Medicine, Chosun University, Gwangju 61453, Republic of KoreaDepartment of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Republic of KoreaDepartment of Anesthesiology, Donghoon Advanced Lengthening Reconstruction Institute, Seongnam 13647, Republic of KoreaDepartment of Anesthesiology and Pain Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan 15355, Republic of Korea<i>Background and Objectives:</i> Patients with type 2 diabetes are at a higher risk of postoperative complications, such as infections, delayed wound healing, and increased mortality compared to non-diabetic patients. <i>Materials and Methods:</i> This prospective randomized study aims to compare the effects of two anesthetics, remimazolam and propofol, on blood glucose levels and immune function in diabetic patients undergoing surgery. Seventy-four diabetic patients undergoing general anesthesia were randomly assigned to receive either remimazolam or propofol. Plasma blood glucose levels, anti-inflammatory markers, and insulin levels were measured during the perioperative period. <i>Results:</i> No statistically significant differences were observed between the remimazolam and propofol groups in terms of neutrophil-to-lymphocyte ratio, anti-inflammatory markers, or glucose levels during the perioperative period (<i>p</i> value > 0.05). <i>Conclusions:</i> These results suggest that there is no difference between propofol and remimazolam in immune function deterioration that occurs due to surgical stress. This study is limited by its small sample size, and in future, larger trials could be conducted to find differences in the effects of blood sugar levels and serum inflammatory markers between the two groups.https://www.mdpi.com/1648-9144/61/3/523anti-inflammatory markersblood sugarglucoseinsulinpropofolremimazolam
spellingShingle Sang Hun Kim
Sang Min Yoon
Ji Hye Ahn
Yoon Ji Choi
Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control
Medicina
anti-inflammatory markers
blood sugar
glucose
insulin
propofol
remimazolam
title Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control
title_full Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control
title_fullStr Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control
title_full_unstemmed Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control
title_short Effect of Remimazolam and Propofol on Blood Glucose and Serum Inflammatory Markers in Patients with Type 2 Diabetes: A Clinical Trial with Prospective Randomized Control
title_sort effect of remimazolam and propofol on blood glucose and serum inflammatory markers in patients with type 2 diabetes a clinical trial with prospective randomized control
topic anti-inflammatory markers
blood sugar
glucose
insulin
propofol
remimazolam
url https://www.mdpi.com/1648-9144/61/3/523
work_keys_str_mv AT sanghunkim effectofremimazolamandpropofolonbloodglucoseandseruminflammatorymarkersinpatientswithtype2diabetesaclinicaltrialwithprospectiverandomizedcontrol
AT sangminyoon effectofremimazolamandpropofolonbloodglucoseandseruminflammatorymarkersinpatientswithtype2diabetesaclinicaltrialwithprospectiverandomizedcontrol
AT jihyeahn effectofremimazolamandpropofolonbloodglucoseandseruminflammatorymarkersinpatientswithtype2diabetesaclinicaltrialwithprospectiverandomizedcontrol
AT yoonjichoi effectofremimazolamandpropofolonbloodglucoseandseruminflammatorymarkersinpatientswithtype2diabetesaclinicaltrialwithprospectiverandomizedcontrol